About Mountaineer Chris Bombardier
Founder of www.AdventuresofaHemophiliac.com.
Has severe hemophilia B.
Has officially summited each of the world’s “Seven Summits.”
His first summit was Mt. Kilimanjaro.
Board member, Save One Life, an international hemophilia nonprofit.
Founder, Backpacks & Bleeders, an outdoor adventure organization for people with bleeding disorders.
Founder, #playitsmart Initiative.
Volunteer, Colorado Chapter, National Hemophilia Foundation.
Currently an adventure educator for GutMonkey.
First person with hemophilia to summit Aconcagua, Mt. Elbrus, Denali and Carstensz Pyramid.
About Director Patrick James Lynch
Has severe hemophilia A.
Co-founder & CEO of Believe Limited, a digital content agency and production company.
Founding board president of the 501(c)(3) Entertainment 2 Affect Change.
Creator, executive producer and star of award-winning bleeding disorders web series Stop The Bleeding!
Director of the World Federation of Hemophilia's Treatment for All web series.
Host and executive producer of The BloodStream Podcast.
2013 Recipient of the Hemophilia Federation of America's Health & Wellness Award.
2014 Recipient of the National Hemophilia Foundation's Meritorious Achievement Award.
2016 Plenary Speaker for World Federation of Hemophilia's World Congress.
About Laurie Kelley
President of LA Kelley Communications, Inc.
Founder and president of Save One Life, Inc.
Author of eleven books on hemophilia, including Raising a Child with Hemophilia.
Founder and publisher of the Parent Empowerment Newsletter.
Founder of HemaBlog.
Founder of Project SHARE, which donates life-saving medicine to people with hemophilia worldwide.
Helped establish hemophilia nonprofits in seven developing countries.
Global coach for leaders in developing countries, to start and develop hemophilia nonprofits.
Has visited 29 developing countries to work with hemophilia patients and nonprofits.
Has worked with hemophilia in developing countries for 20 years.
The filmmaking team, from left to right:
Josh Bragg, Cinematographer
Rob Bradford, Producer & Climber
Carl Trenz, Director of Therapy Development, Octapharma
Chris Bombardier, Mountaineer
Patrick James Lynch, Director/Producer
David Beede, Sound Mixer
For more than 30 years, Octapharma has been focused exclusively on the development and manu- facture of high-quality human proteins for use as medical treatments.
Patients in more than 100 countries are treated with Octapharma therapies for serious chronic and genetic disorders in hematology, immunotherapy and critical care.
Headquartered in Lachen, Switzerland, Octapharma continuously develops sophisticated technolo- gies to help improve the safety of human protein products for patients.
The company’s American subsidiary, Octapharma USA, located in Hoboken, New Jersey, last year introduced NUWIQ®, Antihemophilic Factor (Recombinant) to the U.S. bleeding disorders community.
Octapharma’s commitment to patients also is evident in its product for von Willebrand Disease (VWD) patients – WILATE®, von Willebrand Factor/Coagulation Factor VIII Complex (Human).
Octapharma was the first company to apply the solvent/detergent virus inactivation process to the routine production of Factor VIII concentrates vital to the bleeding disorders community.
Octapharma operates 80 plasma collection centers in the U.S. and Germany, as well as a new state-of-the-art testing laboratory in Charlotte, North Carolina.
The company’s global presence includes more than 6,200 employees, 32 international locations, six production facilities, and five research and development centers.